223 related articles for article (PubMed ID: 25099079)
41. Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic bipolar patients evaluated at a 2-year interval.
Mur M; Portella MJ; Martínez-Arán A; Pifarré J; Vieta E
Acta Psychiatr Scand; 2008 Nov; 118(5):373-81. PubMed ID: 18759809
[TBL] [Abstract][Full Text] [Related]
42. Cognitive functioning in euthymic bipolar I and bipolar II patients.
Dittmann S; Hennig-Fast K; Gerber S; Seemüller F; Riedel M; Emanuel Severus W; Langosch J; Engel RR; Möller HJ; Grunze HC
Bipolar Disord; 2008 Dec; 10(8):877-87. PubMed ID: 19594503
[TBL] [Abstract][Full Text] [Related]
43. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
44. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
45. [What does the subjective assessment of cognitive functioning measure in bipolar disorder? Correlation with the objective assessment of cognitive functioning].
Aydemir O; Kaya E
Turk Psikiyatri Derg; 2009; 20(4):332-8. PubMed ID: 20013424
[TBL] [Abstract][Full Text] [Related]
46. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
[TBL] [Abstract][Full Text] [Related]
47. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcome of cognitive impairment in bipolar disorder.
Torrent C; Martinez-Arán A; del Mar Bonnin C; Reinares M; Daban C; Solé B; Rosa AR; Tabarés-Seisdedos R; Popovic D; Salamero M; Vieta E
J Clin Psychiatry; 2012 Jul; 73(7):e899-905. PubMed ID: 22901360
[TBL] [Abstract][Full Text] [Related]
49. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia.
Malhi GS; Ivanovski B; Hadzi-Pavlovic D; Mitchell PB; Vieta E; Sachdev P
Bipolar Disord; 2007; 9(1-2):114-25. PubMed ID: 17391355
[TBL] [Abstract][Full Text] [Related]
50. Two-year follow-up of treated adolescents with early-onset bipolar disorder: Changes in neurocognition.
Lera-Miguel S; Andrés-Perpiñá S; Fatjó-Vilas M; Fañanás L; Lázaro L
J Affect Disord; 2015 Feb; 172():48-54. PubMed ID: 25451395
[TBL] [Abstract][Full Text] [Related]
51. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.
Ghaemi SN; Gilmer WS; Dunn RT; Hanlon RE; Kemp DE; Bauer AD; Chriki L; Filkowski MM; Harvey PD
J Clin Psychopharmacol; 2009 Jun; 29(3):291-5. PubMed ID: 19440086
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
[TBL] [Abstract][Full Text] [Related]
53. Neurocognitive functioning in patients recently diagnosed with bipolar disorder.
Hellvin T; Sundet K; Simonsen C; Aminoff SR; Lagerberg TV; Andreassen OA; Melle I
Bipolar Disord; 2012 May; 14(3):227-38. PubMed ID: 22548896
[TBL] [Abstract][Full Text] [Related]
54. Can micronutrients improve neurocognitive functioning in adults with ADHD and severe mood dysregulation? A pilot study.
Rucklidge JJ; Harrison R; Johnstone J
J Altern Complement Med; 2011 Dec; 17(12):1125-31. PubMed ID: 22112202
[TBL] [Abstract][Full Text] [Related]
55. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
56. Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with Major Depression.
Gruber S; Rathgeber K; Bräunig P; Gauggel S
J Affect Disord; 2007 Dec; 104(1-3):61-71. PubMed ID: 17360041
[TBL] [Abstract][Full Text] [Related]
57. Theory of mind and facial emotion recognition in euthymic bipolar I and bipolar II disorders.
Martino DJ; Strejilevich SA; Fassi G; Marengo E; Igoa A
Psychiatry Res; 2011 Oct; 189(3):379-84. PubMed ID: 21620484
[TBL] [Abstract][Full Text] [Related]
58. A preliminary longitudinal study on the cognitive and functional outcome of bipolar excellent lithium responders.
Mora E; Portella MJ; Forcada I; Vieta E; Mur M
Compr Psychiatry; 2016 Nov; 71():25-32. PubMed ID: 27592139
[TBL] [Abstract][Full Text] [Related]
59. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).
Weisler RH; Nolen WA; Neijber A; Hellqvist A; Paulsson B;
J Clin Psychiatry; 2011 Nov; 72(11):1452-64. PubMed ID: 22054050
[TBL] [Abstract][Full Text] [Related]
60. Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders.
Vinberg M; Højman P; Pedersen BK; Kessing LV; Miskowiak KW
Acta Neuropsychiatr; 2018 Dec; 30(6):342-349. PubMed ID: 29880069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
